Clinical trials: Blood Plasma Therapy
Multiple Myeloma
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
Allogeneic stem cell (allo SCT) transplantation for multiple myeloma is a potential curative treatment, but is associated with morbidity and treatment related mortality.
- Trial name
- AlloRelapseMM (NCT05675319)
- Testing
- Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD)
- Where
- 30 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Relapsed and Refractory Multiple Myeloma (RRMM)
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Primary Objective: 1. To describe the distribution of treatment regimens and objective response rate (ORR) in a Benchmark Cohort of real-world patients with relapsed/refractory multiple myeloma (RRMM) who initiate treatment after…
- Trial name
- NCT05673967
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma, Plasma Cell Neoplasm
Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction
RATIONALE: Antibodies, such as human immune globulin, can block the growth of abnormal cells in different ways. Some block the ability of abnormal cells to grow and spread.
- Trial name
- NCT00547365
- Testing
- Human immune globulin intravenous (IGIV)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Tennessee
Non-hodgkin Lymphoma, Multiple Myeloma
A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
The purpose of this study is to collect voice recordings and nervous system (neurologic) assessments from people with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) who are receiving standard treatment with CAR T-cell…
- Trial name
- NCT07249528
- Testing
- Audio Tasks
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma
This is an open randomised phase II study evaluating the anti-tumour activity, safety and pharmacology of two dose regimens of IPH2101, a human monoclonal anti-KIR antibody, in patients with multiple myeloma in stable partial…
- Trial name
- REMYKIR (NCT00999830)
- Testing
- IPH2101
- Where
- 9 sites in France
- Volunteers
- 27 people
- Sponsor
- Innate Pharma
Leukemia, Myeloma
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
The goal of this clinical research study is to learn if giving genetically changed immune cells, called T-cells, after chemotherapy will improve the response to a stem cell transplant.
- Conditions
- Leukemia, Myeloma, Myeloproliferative Diseases
- Trial name
- NCT01875237
- Testing
- Fludarabine, Melphalan, Alemtuzumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00004145
- Testing
- anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Chicago
Plasma Cell Myeloma, Plasmacytosis
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase I/II trial studies the safety and best dose of melphalan and bortezomib when given prior to an autologous stem cell transplant and to see how well they work in treating patients with multiple myeloma.
- Conditions
- Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
- Trial name
- NCT02353572
- Testing
- Melphalan, Bortezomib, Dexamethasone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Colorado, Denver
Multiple Myeloma, Refractory Multiple Myeloma
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative and wearable data.
- Trial name
- NCT05053607
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Pack Health
Type 1 Diabetes Mellitus
Insulin Therapy and Lipoproteins' Profile in Type 1 Diabetes.
The aim of the study is to evaluate the effect of insulin therapy in patients with newly diagnosed type 1 diabetes on quantitative and qualitative changes of plasma lipoproteins, with particular emphasis on HDL metabolism, and…
- Trial name
- InLipoDiab1 (NCT02306005)
- Where
- Poland
- Volunteers
- 300 people
- Sponsor
- Poznan University of Medical Sciences
Adverse Effects in the Therapeutic Use of Plasma Substitutes
A Prospective Non-interventional Study to Evaluate the Safety of Methylene Blue Plasma
The objective of this non-interventional study is to gather data on adverse reactions occurring with Methylene Blue plasma administered in a routine clinical practice environment; to know more about their characteristics and…
- Trial name
- NCT02007473
- Where
- 4 sites in Belgium, Greece and 2 more
- Volunteers
- 8 people
- Sponsor
- Maco Productions S.A.S.
Hepatocellular Carcinoma, Cirrhosis
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment
This study will evaluate the usefulness of plasma proteasome levels as a tumor marker of hepatocellular carcinoma (HCC) by studying their variation following curative treatment of HCC.
- Trial name
- NCT01492127
- Testing
- Blood test
- Where
- France
- Volunteers
- 64 people
- Sponsor
- University Hospital, Montpellier
Multiple Myeloma
Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma
The purpose of this study is to improve efficacy of treatment for patients with newly diagnosed multiple myeloma who are not eligible for high-dose chemotherapy followed by autologous stem cell transplantation by Bendamustin…
- Trial name
- BPV (NCT02237261)
- Testing
- Bendamustine, Bortezomib, Prednisone
- Where
- 15 sites in Germany
- Volunteers
- 46 people
- Sponsor
- University Hospital Heidelberg
COVID, Sars-CoV2
Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19
The purpose of this program is to see if giving convalescent plasma to individuals who test positive for COVID-19 may reduce their symptoms and help minimize complications from the illness.
- Conditions
- COVID, Sars-CoV2, Corona Virus Infection
- Trial name
- NCT04445207
- Testing
- Convalescent Plasma
- Where
- United States
- Sponsor
- Jonathan Gerber
Joint Disease
Extracellular Vesicles in Fibrin Gel for Cartilage Repair
This project aims to produce and study in vitro/ex vivo a platelet rich plasma (PRP)-derived fibrin gel loaded with mesenchymal stromal cells (MSC)-extracellular vesicles (EVs), to combine the positive results on cartilage growth…
- Trial name
- GelVex (NCT06713902)
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment
This phase Ib trial studies side effects and best dose of pevonedistat when given together with ixazomib in treating patients with multiple myeloma that has come back or does not respond to treatment.
- Trial name
- NCT03770260
- Testing
- Ixazomib Citrate, Pevonedistat
- Where
- 9 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Neoplasms, Neutropenia
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
The purpose of the study is to explore the safety and efficacy of umbilical cord derived mesenchymal stem cells in treatment-induced myelosuppression in patients with hematologic malignancies.
- Conditions
- Hematologic Neoplasms, Neutropenia, Anemia, Thrombocytopenia
- Trial name
- NCT05672420
- Testing
- umbilical cord derived mesenchymal stem cells
- Where
- 3 sites in China
- Volunteers
- 181 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Osteochondral Fracture of Talus
The Effectiveness of Adding Allogenic Stem Cells After Traditional Treatment of Osteochondral Lesions of the Talus
Randomized, multicentric, prospective, double-blind study: effectiveness of adding allogenic stem cells to a platelet-poor plasma scaffold after arthroscopic debridement and microfractures in patients with osteochondral lesions…
- Trial name
- OLT (NCT03905824)
- Testing
- Allogenic stromal mesenchymal cells derived from the umbilical cord, Debridement and microfracture
- Where
- Chile
- Volunteers
- 70 people
- Sponsor
- University of Chile
Multiple Myeloma
Frontline Therapy in de Novo Multiple Myeloma Patients Under 65
The purpose of this Phase 2 study is to evaluate the efficacy and safety of treatment with bortezomib, lenalidomide and dexamethasone in patients with untreated multiple myeloma.
- Trial name
- IFM2008 (NCT01206205)
- Testing
- Lenalidomide, Bortezomib
- Where
- 9 sites in France
- Volunteers
- 31 people
- Sponsor
- University Hospital, Toulouse
Multiple Myeloma and Plasma Cell Neoplasm
Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003603
- Testing
- cyclophosphamide, dexamethasone, idarubicin
- Where
- United Kingdom
- Volunteers
- 660 people
- Sponsor
- Riverside Haematology Group